Dublin, Feb. 17, 2017 -- Research and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" report to their offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms:
- Injectables
- Solid Dosage Forms
- Liquid & Semi-solid Dosage Forms
The report profiles 112 companies including many key and niche players such as
- Aenova Group (Germany)
- Ajinomoto Althea, Inc. (US)
- Albany Molecular Research Inc. (US)
- Alcami Corporation (US)
- Baxter International, Inc. (US)
- Boehringer Ingelheim GmbH (Germany)
- Catalent Pharma Solutions, Inc. (US)
- Cobra Biologics Holding AB (Sweden)
- CordenPharma International (Germany)
- Dishman Group (India)
- DPx Holdings B.V. (US)
- Fareva Group (Luxembourg)
- Famar Health Care Services (Greece)
- Hospira, Inc. (US)
- Jubilant Life Sciences Limited (India)
- Kemwell Biopharma Pvt. Ltd. (India)
- Lonza Group Ltd. (Switzerland)
- LTS Lohmann Therapie-Systeme AG (Germany)
- NextPharma Technologies Holding Ltd. (UK)
- Nipro Pharma Corporation (Japan)
- Recipharm AB (Sweden)
- Vetter Pharma International GmbH (Germany)
Key Topics Covered:
1. Industry Overview
2. Market Trends & Drivers
3. Competitive Landscape
4. Service Overview
5. Recent Industry Activity
6. Focus On Select Players
7. Global Market Perspective
Total Companies Profiled: 112 (including Divisions/Subsidiaries 125)
- The United States (54)
- Canada (2)
- Japan (7)
- Europe (40)
- - France (6)
- - Germany (10)
- - The United Kingdom (7)
- - Italy (3)
- - Spain (2)
- - Rest of Europe (12)
- Asia-Pacific (Excluding Japan) (21)
- Middle East (1)
For more information about this report visit http://www.researchandmarkets.com/research/ptddk8/pharmaceutical
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Pharmaceutical Manufacturing


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anta Sports Expands Global Footprint With Strategic Puma Stake
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



